No Added Benefit With Pembrolizumab for Myeloma Versus Standard of Care Pembrolizumab added to pomalidomide or lenalidomide for multiple myeloma did not improve overall survival. In addition, pembrolizumab increased the side effects shown in phase 3 trials, a disappointing result since in phase 2 trials, there were benefits from adding pembrolizumab to pomalidomide and dexamethasone. Also, median progression-free survival decreased at 6 months. Read more. |